Aequus Pharmaceuticals Stock Probability of Future OTC Stock Price Finishing Under 0.0148
| AQSZF Stock | USD 0 0 41.79% |
Aequus |
Aequus Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aequus Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aequus Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Aequus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Aequus Pharmaceuticals has high historical volatility and very poor performance | |
| Aequus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aequus Pharmaceuticals has accumulated 26.09 K in total debt with debt to equity ratio (D/E) of 1.39, which is about average as compared to similar companies. Aequus Pharmaceuticals has a current ratio of 0.76, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Aequus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aequus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aequus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aequus to invest in growth at high rates of return. When we think about Aequus Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 2.71 M. Net Loss for the year was (1.81 M) with profit before overhead, payroll, taxes, and interest of 2.69 M. | |
| Aequus Pharmaceuticals has accumulated about 1.39 M in cash with (1.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Aequus Pharmaceuticals shares are held by company insiders |
Aequus Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aequus OTC Stock often depends not only on the future outlook of the current and potential Aequus Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aequus Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 132.6 M |
Aequus Pharmaceuticals Technical Analysis
Aequus Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Aequus OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Aequus Pharmaceuticals. In general, you should focus on analyzing Aequus OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Aequus Pharmaceuticals Predictive Forecast Models
Aequus Pharmaceuticals' time-series forecasting models is one of many Aequus Pharmaceuticals' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Aequus Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Aequus Pharmaceuticals
Checking the ongoing alerts about Aequus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Aequus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Aequus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Aequus Pharmaceuticals has high historical volatility and very poor performance | |
| Aequus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aequus Pharmaceuticals has accumulated 26.09 K in total debt with debt to equity ratio (D/E) of 1.39, which is about average as compared to similar companies. Aequus Pharmaceuticals has a current ratio of 0.76, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Aequus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aequus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aequus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aequus to invest in growth at high rates of return. When we think about Aequus Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 2.71 M. Net Loss for the year was (1.81 M) with profit before overhead, payroll, taxes, and interest of 2.69 M. | |
| Aequus Pharmaceuticals has accumulated about 1.39 M in cash with (1.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Aequus Pharmaceuticals shares are held by company insiders |
Other Information on Investing in Aequus OTC Stock
Aequus Pharmaceuticals financial ratios help investors to determine whether Aequus OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aequus with respect to the benefits of owning Aequus Pharmaceuticals security.